Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: A multicenter, randomized, controlled trial

Circulation

Volumn 104, Issue 1, 2001, Pages 52-57

  Ammirati, Fabrizio ^a,b   Colivicchi, Furio ^a   Santini, Massimo ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Pacing; Syncope; blockers

Indexed keywords

ATENOLOL;

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYNCOPE; TILT TABLE TEST; TREATMENT INDICATION;

EID: 0035800092     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc2601.091708     Document Type: Article

References (25)

1. Pathophysiological aspects of neurocardiogenic syncope: Current concepts and new perspectives
2. Neurally mediated syncopal syndromes: Pathophysiological concepts and clinical evaluation
3. Impairment of physical and psychosocial function in recurrent syncope
4. Role of pacing in the treatment of vasovagal syncope
5. Pharmacotherapy of neurally mediated syncope
6. Pharmacologic approaches to the therapy for vasovagal syncope
7. Randomized, double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results
8. Midodrine: A role in the management of neurocardiogenic syncope
9. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-blind, placebo-controlled study
10. Permanent pacing for cardioinhibitory malignant vasovagal syndrome
11. Clinical experience with Thera DR rate drop response pacing algorithm in carotid sinus syndrome and vasovagal syncope
12. The North American Vasovagal Pacemaker Study (VPS): A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope
13. Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope: Pacemaker versus no therapy: A multicenter randomized study
14. Evaluation and outcome of emergency room patients with transient loss of consciousness
15. Evaluation and prognostic classification of patients with syncope
16. The value of clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block and neurocardiogenic syncope
17. Neurocardiogenic syncope
18. Head-up tilt testing potentiated with low-dose sublingual isosorbide dinitrate: A simplified time-saving approach for the evaluation of unexplained syncope
19. Do symptoms predict cardiac arrhythmias and mortality in patients with syncope?
20. DDD pacing with rate drop response function versus DD1 with rate hysteresis pacing for cardioin-hibitory vasovagal syncope
21. Timing of first syncope recurrence predicts syncope frequency following a positive tilt table test
22. Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope
23. Vasovagal syncope
24. Effect of beta blockers on the time to first syncope recurrence in patients after a positive tilt test
25. Cardiac pacing for the prevention of vasovagal syncope